Developing a platform to create therapeutic exosomes for drug delivery
Official title: A Convergent Bioengineered Platform for Multifunctional Therapeutic Exosomes
Funded at University of Notre Dame · NIH-10910010 · Data updated 2026-11-12
This study is exploring a new way to make tiny delivery vehicles called exosomes that can carry cancer-fighting drugs right to the areas that need them, which could help patients get better treatment with fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $374,300 |
| NIH project number | 5R35GM150608-02 |
| Project ID | NIH-10910010 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancer who may benefit from advanced drug delivery systems.
✕Less likely to help
Patients with non-cancerous conditions or those not requiring drug delivery improvements may not receive benefits from this research.
What this research studies
This research focuses on creating a bioengineered platform that efficiently manufactures therapeutic exosomes, which are tiny vesicles that can carry drugs. The approach involves loading anticancer drugs and therapeutic nucleic acids into these exosomes, enhancing their ability to deliver treatment directly to targeted areas in the body. By utilizing exosomes, the research aims to improve drug delivery across the blood-brain barrier and enhance the effectiveness of cancer therapies. Patients may benefit from more effective treatments with fewer side effects compared to traditional drug delivery methods.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments with reduced side effects.
How similar studies have gone: Other research has shown promising results using exosomes for drug delivery, indicating potential success for this approach.
Where this research is happening
-
University of Notre Dame
Notre Dame, United States Active
Researchers
- Principal investigator: Wang, Yichun — University of Notre Dame
- Study coordinator: Wang, Yichun
Related research
Other NIH-funded projects on the same topics.
-
Designer covalent blockers to stop IgE-driven allergic reactions
A new approach aims to block IgE antibodies that trigger allergic reactions in people with allergic asthma, potentially reducing severe symptoms without broad immune suppression.
-
A life-course view of how early adversity shapes health as people grow up
This NIH grant looks at how tough experiences in childhood and adolescence affect health and aging later in life, using data from people and animal studies to understand why some outcomes are worse and how social factors can help.
-
How a simple, evidence-based approach helps mothers and kids in Peru feel better
A study tests a flexible, lay-delivered mental-health program called CETA for mothers of young children in Lima to improve family well-being.
-
Open-Source tools to test conversational AI for dementia care
A multilingual AI benchmarking project aims to help improve chatbots and virtual assistants used in Alzheimer’s and related dementias, with open tools and datasets for researchers and clinicians.
-
Decoding how human CD8+ T cells recognize donor HLA in transplant rejection
This project studies why certain T cells attack transplanted kidneys, with the goal of understanding which cells drive acute rejection and how they recognize donor HLA.
-
Targeted antibody-guided nanoparticles to treat CMV infection
A new treatment approach combines CMV-targeting antibodies with drug-loaded nanoparticles to deliver antiviral medicine directly to infected cells, aiming to improve efficacy and reduce side effects for people with CMV infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.